Nautilus Biotechnology Target Price

NAUT Stock

USD 2.88 -0.06 -2.04%

Nautilus Biotechnology's current Target Price is shown along with the formula used to calculate it. The reported reading aligns with the most recent filing period.

4.0

The disclosed Target Price for Nautilus Biotechnology corresponds to the current reporting dataset. Reported values correspond to the most recent financial period.

Target Price Peer Comparison

The Target Price peer comparison for Nautilus Biotechnology contextualizes its performance relative to the competitive set. This peer-based view of Target Price evaluates Nautilus Biotechnology relative pricing within the sector. A sustained gap between Nautilus Biotechnology's Target Price and peer averages deserves closer fundamental investigation. The resulting analysis reveals whether Nautilus Biotechnology stands out within its competitive group.

Nautilus Biotechnology is currently under evaluation in target price relative to competitors.

Important Fundamentals

	Return On Equity TTM	-0.34
	Return On Asset TTM	-0.2
	Current Valuation	301.53 M
	Shares Outstanding	127.08 M
	Shares Owned By Insiders	33.20 %
	Shares Owned By Institutions	44.80 %
	Number Of Shares Shorted	638.94 K
	Price To Book TTM	2.55 X
	EBITDA TTM	-52.54 M
	Net Income TTM	-59 M
	Cash And Equivalents TTM	299.34 M
	Cash Per Share TTM	2.40 X
	Total Debt TTM	30.02 M
	Debt To Equity TTM	0.09 %
	Current Ratio TTM	49.75 X
	Book Value Per Share TTM	1.24 X
	Cash Flow From Operations TTM	-50.7 M
	Short Ratio TTM	1.51 X
	Earnings Per Share	-0.46 X
	Target Price	4.0
	Number Of Employees	130
	Trailing Beta	0.75
	Market Capitalization TTM	373.61 M
	Total Asset TTM	191.11 M
	Retained Earnings TTM	-332.02 M
	Working Capital TTM	98.01 M
	Net Asset	191.11 M

Financial Metrics, Fundamentals & Methodology

Nautilus Biotechnology's financial profile is best read through income generation trends and leverage discipline. The mix of equity and liabilities defines Nautilus Biotechnology's aggregate capital risk. For the latest reporting period, Nautilus Biotechnology reports EPS loss of 0.46, current ratio of 49.75, debt-to-equity of 0.09.

Nautilus Biotechnology figures are aggregated from periodic company reporting and market reference feeds and normalized across reporting formats. Professional analyst research is incorporated when coverage is available. Financial statement fields are presented under issuer-reported GAAP or IFRS accounting conventions.

Editorial review and methodology oversight provided by: Michael Smolkin, Member of Macroaxis Board of Directors